Option Care Health, Inc. (OPCH) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: while there are positive aspects such as strong performance in acute therapies and growth in the IG Neuro portfolio, there are significant headwinds from the Stelara transition and increased gross profit headwinds. The company's confidence in its guidance and strategic initiatives are offset by concerns about competitive pressures and unclear management responses in some areas. The market cap suggests moderate sensitivity, leading to a neutral prediction for stock price movement over the next two weeks.
Key Financial Performance
Revenue $1.4 billion, up slightly over 1% compared to last year. Acute revenue growth was in the high single digits, while chronic revenue declined slightly. Total company revenue growth was negatively impacted by approximately 600 basis points due to headwinds within the CID portfolio.
Gross Profit Declined slightly over last year due to the decline in chronic revenue. The gross profit dollar headwind related to the CID portfolio was estimated at $25 million to $35 million but is now estimated at approximately $55 million for the year, including additional patient loss.
SG&A (Selling, General, and Administrative Expenses) Grew 4%, reflecting the wraparound of investments made in 2025 and ongoing investments in commercial resources to support future growth.
Adjusted EBITDA $105 million, down 6% over prior year but in line with expectations. Acute performance and execution on strategic initiatives offset the dynamics in the chronic portfolio.
Adjusted EPS $0.40, flat with prior year, with an uplift of $0.02 from the year-over-year benefit of share repurchases.
Operating Cash Flow Usage of $12 million, in line with seasonal expectations. First quarter is typically the lowest due to seasonal patterns and incentive compensation payments. Improvement was seen from early inventory management initiatives.
Net Debt to Leverage Ratio 2.2x at the end of the quarter.
Revolving Credit Facility Expanded from $400 million to $850 million to enhance financial flexibility.
Ambulatory Infusion Clinic Utilization Visits grew 14% year-over-year, driven by commercial and operational collaboration and market access expansion.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Rare and Orphan Programs: Launch delays or slower ramp for a few programs due to regulatory or commercial launch readiness, impacting growth expectations for later in the year.
Oncology Portfolio: Continued traction observed, representing a small but growing part of the business with meaningful growth opportunities as market dynamics shift.
Infused and Injectable Drugs: Strong pipeline observed, with over 600 therapies in the portfolio and active engagement with pharma manufacturers for new-to-market products.
Ambulatory Infusion Clinics: Utilization increased with visits growing 14% year-over-year, now operating in 28 locations with advanced practitioner capabilities in key markets.
Site of Care Initiatives: Existing initiatives performing better than expected, providing cost savings to health plans and increased choice and satisfaction to members.
Commercial Team Expansion: Increasing the strength and size of the commercial team, realigning resources, and rebalancing coverage across top specialty practices and accounts.
Operational Excellence: Focus on capturing therapy-level economics, enhancing admission conversion rates, and deploying technology for seamless workflow from referral to start.
Inventory Management: Improved supply and demand alignment observed, with additional benefits expected from working capital initiatives as the year progresses.
Revenue Guidance Adjustment: Full-year net revenue guidance adjusted to $5.675 billion to $5.775 billion, reflecting a 1% growth due to industry dynamics and lower CID patient retention.
Capital Allocation Strategy: Expanded revolving credit facility from $400 million to $850 million to enhance financial flexibility, aligning with capital allocation priorities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Growth: Revenue growth of 1% did not meet expectations, with chronic therapy portfolio experiencing a slight decline and slower-than-expected growth in certain therapies. This includes a significant reset in patient census and unfavorable therapy mix, impacting recurring revenues.
Chronic Inflammatory Portfolio (CID): Higher-than-expected patient loss and therapy mix changes in the CID portfolio led to a $55 million gross profit headwind for the year, higher than the previously estimated $25-$35 million. This will take time to recover due to the recurring nature of revenues.
Regulatory and Commercial Launch Delays: Launch delays or slower ramp for rare and orphan programs due to regulatory or commercial readiness issues will impact growth expectations for later in the year.
Operational Challenges: Increased patient benefit reverification and reauthorization requirements doubled compared to last year, elongating approval decisions and impacting patient census and therapy transitions.
Strategic Execution Risks: Slower-than-expected growth in targeted specialty call points and challenges in accelerating new therapy adoption have hindered revenue growth.
Economic Pressures: Ongoing economic pressures across healthcare are creating challenges in maintaining cost efficiency and operational competitiveness.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year Revenue Guidance: The company has revised its full-year revenue guidance to a range of $5.675 billion to $5.775 billion, representing just over 1% growth versus the prior year at the midpoint. This adjustment reflects a higher-than-expected negative 600 basis point revenue growth headwind due to lower CID patient retention and therapy mix.
Full Year EBITDA and Adjusted EPS Guidance: The company is maintaining its full-year EBITDA guidance of $480 million to $505 million and adjusted EPS range of $1.82 to $1.92, corresponding to growth at the midpoint of 5% and 9%, respectively. The EBITDA guidance incorporates a forecasted $55 million CID portfolio headwind, expected to be realized evenly through the year.
Second Quarter Sequential Growth: The company expects second-quarter sequential revenue growth in the mid-single digits and EBITDA sequential growth in the high single digits, reflecting consistent seasonality with prior years.
Operating Cash Flow Target: The company has adjusted its operating cash flow target to at least $320 million, incorporating the lower revenue and cash-based EBITDA reduction.
Pharma Program Development: The company is preparing for new pharma program launches later in the year and expects these opportunities to drive growth. It is actively pursuing additional opportunities to support pharma partners in the commercialization of new-to-market products.
Ambulatory Infusion Clinic Growth: The company continues to see growth in its ambulatory infusion clinic utilization, with visits growing 14% year-over-year. It plans to leverage its network of infusion suites and clinics to drive further growth.
Oncology Portfolio Growth: The company sees meaningful growth opportunities in its oncology portfolio as market dynamics shift and more oncology products move into the infusion clinic and home setting.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: In the first quarter, the company repurchased over $17 million of its shares.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you explain the increase in the headwind on the gross profit side versus the initial assumptions?
A:The increase in the gross profit headwind to $55 million (from the initial $25-$35 million) was primarily due to changes in patient census and therapy mix. The loss of Stelara patients and an unfavorable therapy mix contributed to this increase. The company now assumes this headwind will pattern out evenly through the rest of the year.
Q:What caused the delays in benefit reverification and how will it impact future quarters?
A:The delays were caused by a significant increase in patients switching health plans, benefit design changes, and formulary changes. This elongated the reverification process, with many determinations made only by March. The company believes it has now completed the reverification process and expects sequential growth moving forward.
Q:How will the company achieve the high single-digit EBITDA growth in Q2 and the large ramp-up in the back half of the year?
A:The company plans to achieve this through strong performance in acute therapies, growth in the IG Neuro portfolio, partnerships with payers, and cost reductions. They also expect natural seasonal growth and rebuilding the patient census to contribute to the ramp-up.
Q:What led to the lower conversion rates and how will the company address this issue?
A:Lower conversion rates were due to elongated reverification processes, preferred biosimilars by PBMs, and higher standards for patient qualifications. The company plans to address this by ensuring adequate staffing, improving responsiveness, and focusing on new referrals and patients.
Q:Is the company confident in its guidance despite the headwinds?
A:Yes, the company is confident in its guidance due to strong performance in other parts of the business, cost reduction efforts, and investments in commercial resources. They believe they can achieve sequential growth and maintain their EBITDA and EPS guidance.
Q:What is the impact of the Stelara reset on future years?
A:The company does not expect additional headwinds from Stelara in 2026 or carryover into 2027. They believe the reset is complete and have clarity on the patient census moving forward.
Q:How does the company view the competitive landscape and its ability to regain market share?
A:The company acknowledges the competitive environment but believes in its strong foundation, local responsiveness, and ability to provide clinical value. They plan to reaccelerate growth through enhanced commercial execution and service levels.
Q:What are the company's capital deployment priorities?
A:The company prioritizes organic investments to drive growth, followed by M&A activity and periodic share buybacks. They recently expanded their revolving credit facility to support M&A opportunities.
Q:How does the company plan to address the chronic growth challenges?
A:The company plans to focus on rebuilding the patient census, enhancing commercial resources, and driving growth in other specialty areas. They are confident in their ability to reaccelerate growth despite the challenges.
Q:What is the company's outlook for acute revenue growth?
A:The company expects to continue above-market growth in acute therapies, driven by strong execution, deepening relationships with referral sources, and leveraging their nursing network.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing whether the competitive landscape and patient acquisition costs might permanently impact their ability to regain market share. They also did not provide specific details on how they plan to address the therapy mix challenges beyond general statements about commercial execution and service enhancements.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CID reset
CID specialty
Chief Financial
Chronic Inflammatory
Conference today
Executive Vice
Financial Officer
Ig Neuro
Inflammatory Portfolio
Net Promoter
Vice President
choice
commitment
conversion
coverage
delay
disease
excellence
health care
health system
hospital health
industry dynamic
infusion clinic
launch
offering
oncology
orphan program
pharma partner
portfolio opportunity
provider
satisfaction
specialty pharmacy
suite clinic
therapy mix
therapy portfolio
OPCH Transcript
Option Care Health, Inc. (OPCH) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call reveals mixed signals: while there are positive aspects such as strong performance in acute therapies and growth in the IG Neuro portfolio, there are significant headwinds from the Stelara transition and increased gross profit headwinds. The company's confidence in its guidance and strategic initiatives are offset by concerns about competitive pressures and unclear management responses in some areas. The market cap suggests moderate sensitivity, leading to a neutral prediction for stock price movement over the next two weeks.
Option Care Health, Inc. (OPCH) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call summary reveals strong financial performance, optimistic guidance, and strategic investments, leading to a positive sentiment. The Q&A section supports this with management's confidence in growth opportunities and strategic acquisitions. Despite some uncertainties, such as biosimilar impacts, the overall tone is positive, with raised revenue and EPS guidance, and a focus on operational efficiency. Given the market cap of approximately $4.86 billion, these factors suggest a moderate positive stock price reaction in the coming weeks.
Option Care Health, Inc. (OPCH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Option Care Health, Inc. (OPCH) Presents at Bank of America Home Care Conference Transcript
Neutral12-8
OPCH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
